title: SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention.
abstract: Abstract Ovarian cancer ranks as the second most common tumor of the female reproductive system, with a large burden on global public health. Therefore, the identification of novel molecular targets and diagnostics is an urgent need for many women affected by this disease. To this end, the human transcription factor SOX2 is involved in a wide range of pathophysiological roles, such as the maintenance of stem cell characteristics and carcinogenesis. To date, in most studies, SOX2 has been shown to promote the development of cancer, although its inhibitory roles in cancer have also been reported. However, to the best of our knowledge, the role of SOX2, specifically in ovarian cancer cells, has not been examined in detail. In this article, we report, for the first time, that SOX2 promotes migration, invasion, and clonal formation of ovarian cancer cells. We further observed that SOX2 targeted FN1, a key gene that regulates cell migration in ovarian cancer. Our findings collectively suggest that the SOX2-FN1 axis is a key pathway in mediating the migration and invasion of ovarian cancer cells. This pathway offers crucial molecular insights and promises to develop putative candidate therapeutic interventions in women with ovarian cancer.
authors.affiliation: 1 Systems Biology Division and Propriumbio Research Center, Zhejiang-California International Nanosystems Institute (ZCNI), Zhejiang University , Hangzhou, China .
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Lou
authors.forename: Xu
authors.initials: X
authors.lastname: Han
authors.forename: Chengmeng
authors.initials: C
authors.lastname: Jin
authors.forename: Wei
authors.initials: W
authors.lastname: Tian
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
authors.forename: Dong
authors.initials: D
authors.lastname: Ding
authors.forename: Lihua
authors.initials: L
authors.lastname: Cheng
authors.forename: Bingding
authors.initials: B
authors.lastname: Huang
authors.forename: Huawei
authors.initials: H
authors.lastname: Jiang
authors.forename: Biaoyang
authors.initials: B
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D005353:Fibronectins / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D011401:Promoter Regions, Genetic; D055748:SOXB1 Transcription Factors / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; C067625:FN1 protein, human; D005353:Fibronectins; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9; D002945:Cisplatin
references.citation: PLoS One. 2011;6(11):e26740
references.pmid: 22069467
references.citation: Methods Mol Med. 2001;57:163-74
references.pmid: 21340898
references.citation: Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602
references.pmid: 20705681
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Cell. 2009 May 15;137(4):647-58
references.pmid: 19409607
references.citation: J Cancer Res Clin Oncol. 2011 Jan;137(1):131-7
references.pmid: 20349085
references.citation: Am J Pathol. 2013 Mar;182(3):954-64
references.pmid: 23306155
references.citation: PLoS One. 2011 Jan 27;6(1):e16617
references.pmid: 21304604
references.citation: OMICS. 2010 Aug;14(4):369-84
references.pmid: 20726797
references.citation: Hum Pathol. 2012 Sep;43(9):1405-12
references.pmid: 22401770
references.citation: Cancer Metastasis Rev. 1995 Sep;14(3):173-89
references.pmid: 8548867
references.citation: Oncol Rep. 2011 Nov;26(5):1069-74
references.pmid: 21811761
references.citation: BMC Genomics. 2011 Jan 06;12:11
references.pmid: 21211035
references.citation: Am J Cancer Res. 2011;1(1):71-84
references.pmid: 21968440
references.citation: Biochimie. 2010 Oct;92(10):1422-34
references.pmid: 20638438
references.citation: Biochem Biophys Res Commun. 2013 Jan 25;430(4):1319-21
references.pmid: 23261429
references.citation: J Biol Chem. 2005 Jul 1;280(26):24371-9
references.pmid: 15863505
references.citation: Dtsch Arztebl Int. 2011 Sep;108(38):635-41
references.pmid: 22025930
references.citation: Cancer Res. 1997 Dec 1;57(23):5416-20
references.pmid: 9393769
references.citation: Genes Dev. 2003 Jan 1;17(1):126-40
references.pmid: 12514105
references.citation: Curr Opin Cell Biol. 2002 Oct;14(5):624-32
references.pmid: 12231359
references.citation: PLoS One. 2012;7(8):e41335
references.pmid: 22912670
references.citation: Nucleic Acids Res. 2012 Aug;40(14):6725-40
references.pmid: 22561374
references.citation: Cancer Res. 2011 Oct 15;71(20):6463-74
references.pmid: 21868760